https://www.avient.com/sites/default/files/2020-10/antimicrobial-dental-case-study.pdf
Further, the
lower let-down ratio represented a 30% cost savings
per year.
https://www.avient.com/sites/default/files/2021-12/avient-sarl-czech-republic-branch-register-extract-dec-3-2021.pdf
Czech Republic Branch
Údaje platné ke dni: 3. prosince 2021 03:45 1/1
Výpis
z obchodního rejstříku, vedeného
Městským soudem v Praze
oddíl , vložka A 78870
Datum vzniku a zápisu: 30. srpna 2018
Spisová značka: A 78870 vedená u Městského soudu v Praze
Označení odštěpného
závodu:
Avient S.à r.l., Czech Republic Branch
Sídlo: Pobřežní 620/3, Karlín, 186 00 Praha 8
Identifikační číslo: 074 10 026
Právní forma: Odštěpný závod zahraniční právnické osoby
Předmět podnikání:
Výroba, obchod a služby neuvedené v přílohách 1 až 3 živnostenského zákona
Vedoucí odštěpného závodu:
LÁSZLÓ MEDNYÁNSZKY, dat. nar. 23. listopadu 1967
9400 Sopron, Ösvény 7, Maďarská republika
Zřizovatel - zahraniční osoba:
Avient S.à r.l.
9638 Pommerloch, Route de Bastogne 19, Lucemburské velkovévodství
Registrační číslo: B226205
Právní forma: společnost s ručením omezeným
Statutární orgán zřizovatele - zahraniční osoby:
HOLGER HANS KRONIMUS, dat. nar. 26. ledna 1968
76571 Gaggenau, Adolf Dambach-Strasse 2, Spolková republika Německo
Den vzniku funkce: 4. července 2018
Den vzniku členství: 4. července 2018
CHRISTOPH PALM, dat. nar. 16. května 1963
9638 Pommerloch, Route de Bastogne 19, Lucemburské velkovévodství
Den vzniku funkce: 4. července 2018
Den vzniku členství: 4. července 2018
ZANETA GABRIELA POTOCZNY, dat. nar. 17. října 1974
9638 Pommerloch, route de Bastogne 19, Lucemburské velkovévodství
Den vzniku funkce: 27. února 2019
Den vzniku členství: 27. února 2019
NORBERT MERKLEIN, dat. nar. 3. května 1964
4132 Muttenz, Rothausstrasse 61, Švýcarská konfederace
Den vzniku funkce: 18. ledna 2021
Den vzniku členství: 18. ledna 2021
Počet členů: 4
Společnost je platně vázána nebo zastupována vůči třetím osobám takto: má-li
Společnost více než jednoho jednatele, pak podpisem kteréhokoli jednatele.
https://www.avient.com/sites/default/files/2024-01/AVNT January IR Presentation_w Non-Gaap Recs.pdf
Avient 2011, 2018 and 2021 multiples reflect trailing 12 months EBITDA at December 31.
28
EV / 2023E EBITDA
6.5
8.5
11.0 10.8
16.1 15.5
14.1 14.0
10.3
21.0
19.0
14.3
12.1 11.8 11.7 11.5
9.7
11
21
23
PM AV
FM
Avient Historic Multiple
Avient Specialty
Other Specialty /
AP P E N DI X
30
Performance
Additives
16%
Pigments
12%
TiO2
Dyestuffs
2%
Polyethylene
Nylon
Polypropylene
Styrenic Block
Copolymer
Other Raw
Materials
33%
~40% hydrocarbon based
(Grey shaded materials are hydrocarbon based,
includes portion of “Other Raw Materials”)
Non-hydrocarbon
based materials
2022 pro forma results for the acquisition of Avient Protective Materials
RAW MATERIAL BASKET
SEGMENT DATA
U.S. & Canada
40%
37%
18%
2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY
GEOGRAPHY REVENUESEGMENT FINANCIALS
Building and
END MARKET REVENUE
$2,355M $402M
$1,300M $272M
Sales EBITDA
Specialty Engineered Materials
Color Additives and Inks
$592M$3,653M
(1)
9%
32
(1) Total company sales and adjusted EBITDA of $3,653M and $592M, respectively, include intercompany sales eliminations and corporate costs
2022 REVENUE | $2 .4 BILLION
US & Canada
34%
38%
END MARKET REGION
33
34%
21%
Building &
1% Energy
2%
COLOR, ADDITIVES & INKS
2022 PRO FORMA REVENUE | $1 .3 BILLION
US & Canada
52%
35%
34
19%
8%Industrial
16%
9% Defense
Building &
END MARKET REGION
SPECIALTY ENGINEERED MATERIALS
32%
27%
14%
Building &
3%
1% Defense
1%
(18% of sales)
9%
2022 PROFORMA AVIENT REGIONAL SALES
27%
14%
17%
Building &
(37% of sales)Transportation
12%
Building &
US &
Canada
(40% of sales)
7%
56%
23%
7%
Building &
1%
LATAM
(5% of sales)
3%
35
BY END MARKET
Reconciliation of Non-GAAP Financial Measures
(Unaudited)
(Dollars in millions, except for per share data)
Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders
and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special
items, to assess performance and facilitate comparability of results.
Three Months Ended
September 30, 2023
Three Months Ended
September 30, 2022
Reconciliation to Condensed Consolidated Statements of Income: $ EPS $ EPS
Net income (loss) from continuing operations attributable to Avient
shareholders $ 5.1 $ 0.06 $ (27.4) $ (0.30)
Special items, after tax 32.0 0.35 68.3 0.75
Amortization expense, after-tax 15.2 0.16 $ 13.4 $ 0.14
Adjusted net income / EPS $ 52.3 $ 0.57 $ 54.3 $ 0.59
September 30,
Reconciliation to EBITDA and Adjusted EBITDA: 2023 2022
Sales - GAAP $ 753.7 $ 823.3
Pro Forma APM adjustments — 60.7
Pro forma adjusted sales $ 753.7 $ 884.0
Net income from continuing operations – GAAP $ 5.1 $ (27.8)
Income tax (benefit) expense (0.1) (1.2)
Interest expense, net 30.3 37.3
Depreciation and amortization 46.4 39.8
EBITDA from continuing operations $ 81.7 $ 48.1
Special items, before tax 43.2 82.0
Interest expense included in special items (2.2) (10.0)
Depreciation and amortization included in special items — (0.8)
Adjusted EBITDA $ 122.7 $ 119.3
Pro forma APM adjustments — 17.2
Pro forma adjusted EBITDA $ 122.7 $ 136.5
Pro forma adjusted EBITDA as a % of sales 16.3 % 15.4 %
1
Year Ended
December 31,
Reconciliation to EBITDA and Adjusted EBITDA: 2006 2018
Sales $ 2,622.4 $ 3,533.4
Net income from continuing operations – GAAP $ 133.5 $ 160.8
Income tax expense 29.7 36.4
Interest expense, net 63.1 62.8
Depreciation and amortization 57.1 91.5
EBITDA from continuing operations $ 283.4 $ 351.5
Special items, before tax (34.0) 59.5
Depreciation and amortization included in special items — (3.0)
JV - equity income (107.0) —
Adjusted EBITDA $ 142.4 $ 408.0
Adjusted EBITDA as a % of sales 5.4 % 11.5 %
Reconciliation to EBITDA and Adjusted EBITDA:
December 31, 2022
Net loss from continuing operations – GAAP $ (16.6)
Income tax benefit (60.8)
Interest expense, net 49.4
Depreciation and amortization 48.6
EBITDA from continuing operations $ 20.6
Special items, before tax 104.3
Interest expense included in special items (16.0)
Depreciation and amortization included in special items (1.5)
Adjusted EBITDA $ 107.4
Reconciliation of Pro Forma Adjusted Earnings per Share:
Three Months Ended
December 31, 2022
Net loss from continuing operations attributable to Avient
shareholders $ (17.0)
Special items, after tax 38.3
Amortization expense, after-tax 14.6
Adjusted net income from continuing operations excluding special
items 35.9
Pro forma adjustments* 2.5
Pro forma adjusted net income from continuing operations attributable
to Avient shareholders $ 38.4
Weighted average diluted shares 91.7
Pro forma adjusted EPS - excluding special items pro forma for APM
acquisition $ 0.42
* Pro forma adjustment to reflect APM results for the period before Avient ownership including the impacts of debt financing and paydown of
debt with net proceeds from the Distribution sale.
2
AVNT January IR Presentation.pdf
Avient corporation�investor presentation
DISCLAIMER
Slide Number 3
Creating a world-class�sustainable organization
Top-tier sustainability performance�and recognition
What we do: We are a formulator
Slide Number 7
Avient protective materials �First Year
Slide Number 9
Slide Number 10
Slide Number 11
Slide Number 12
Slide Number 13
Slide Number 14
Slide Number 15
Slide Number 16
Slide Number 17
Slide Number 18
Slide Number 19
Slide Number 20
Slide Number 21
Slide Number 22
Slide Number 23
Slide Number 24
Slide Number 25
Avient is asset light
Free cash flow conversion
Multiple expansion
Slide Number 29
Slide Number 30
Slide Number 31
2022 pro forma segment, end market and Geography
Color, Additives & Inks
Specialty Engineered Materials
Slide Number 35
IR Deck - AVNT-2023.09.30 Non GAAP Recs.pdf
Attachment
https://www.avient.com/sites/default/files/2024-12/Terms and Conditions of Sale for Indonesia %28English translation%29.pdf
Buyer must give Seller
written notice of the existence of each claim involving Product
(whether based in contract, breach of warranty, negligence, strict
liability, other tort or otherwise) within the earlier of thirty (30) days
after receipt of the quantity of Product forming the basis for the
claim or applicable shelf-life expiration, if any.
In the event of any dispute of difference
arising out of or in connection to these Terms the Buyer and
Seller shall use their best endeavors to settle such disputes or
differences through amicable discussions within 30 days of the
commencement of negotiation or discussion by the Buyer and
Seller.
The Buyer and Seller agree that in any circumstances,
the appointed arbitrators through the BANI Rules will have the
power to examine and decide on the dispute between the Buyer
and Seller and to take necessary measures in relation to the
registration of the arbitration award according to Law No. 30 of
1999 on Arbitration and Alternative Dispute Resolution
(“Arbitration Law”).
https://www.avient.com/sites/default/files/2022-06/MEVOPUR Bio-based Solutions Application Bulletin_CN %281%29.pdf
在不限制本声明的一般性的情况下,不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用:
(1) 接触人体组织或体液长达30天或更长时间;
(2)“整形”(整容或重建)手术;
(3) 生殖植入物或任何节育器械;或者
(4) 用于支持或维持人类生命的永久性(超过30天)植入式医疗器械中的任何关键组件。
https://www.avient.com/sites/default/files/2022-05/ColorMatrix Amosorb Solo Technical Bulletin.pdf
The European Union has encouraged and acted on
the need for circular packaging by implementing
many initiatives, including mandating legislation
in order to achieve an ambitious target of 25%
rPET being utilized in PET packaging by the year
2025, and then scaling this figure up to 30% for the
overall plastic packaging industry by 2030.1
With 47% of PET demand in Europe used to
produce bottles,2 it is no surprise PET has long
been at the center of this green revolution.
Scenarios for 2030 predict that of the 1300kt of
PET material coming from PET bottles collected
from the market yearly, between 20 to 30% will be
colored bottles;2 these will enter their respective
sorting and collection systems to ultimately
produce rPET material that will be fed as new raw
material for non-food PET applications.
https://www.avient.com/sites/default/files/2022-08/MEVOPUR Special Effect Colors Application Bulletin_CN.pdf
在不限制本声明的一般性的情况下,不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用:
(1) 接触人体组织或体液长达30天或更长时间;
(2)“整形”(整容或重建)手术;
(3) 生殖植入物或任何节育器械;或者
(4) 用于支持或维持人类生命的永久性(超过30天)植入式医疗器械中的任何关键组件。
https://www.avient.com/sites/default/files/2023-11/Wire _ Cable Selection Guide_CN 11.08-1.pdf
Wire _ Cable Selection Guide_CN 11.09-1
电线 & 电缆
解决方案
特种工程材料
产品选择指南
用于电线与电缆行业的
高性能绝缘材料、护套和交联配方
Syncure™ XLPE
交联聚乙烯配方
室温自然交联
耐热、耐油、抗蠕变和耐磨
低温特性
设备投入低
拥有不含十溴二苯烷产品规格
UL/ CSA 公告
ECCOH™
低烟无卤配方
防火安全
低烟,无卤配方(LSFOH)
耐化学品
Maxxam™ FR
阻燃聚乙烯配方
替代FEP
耐火性
阻燃性-UL 444 & 阻燃黄卡
低介电性
薄壁挤出
ECCOH™ XL
交联解决方案
无卤,低烟,低毒,低腐蚀性
优异的机械性能 & 导电性能
易于加工
90℃的工作温度
室温自然交联
Maxxam™ SY
发泡阻燃配方
低介电
均匀的发泡
抗冲击、耐热
易于化学发泡
FireCon™ CPE
绝缘护套配方
适用于恶劣环境
低温性能
耐日光
Synprene™
阻燃热塑性弹性体
柔性
抗低温脆化(LTB)
耐化学品
易于着色
耐热、耐油、耐蠕变、耐磨损
耐低温
资本投入低
低压电力电缆
横向火焰 UL 44Syncure™ S100FH
Syncure™ S100FH-XUV 横向火焰,抗紫外线
横向火焰、FV-1火焰、抗紫外线
VW-1火焰
VW1、抗紫外线
非阻燃
非阻燃
横向火焰,不含DBDPE
UL 44、UL 4703
CSA 22.2
NSF 61
电力电缆系统绝缘
Syncure™ S100FH-UV
Syncure™ S100FV
Syncure™ S100FV-UV
Syncure™ S112NA
Syncure™ S120NA
VW-1,不含DBDPE UL 44Syncure™ S200FV
Syncure™ S200FH
低烟无卤、低毒性、耐腐蚀 EN50618ECCOH™ XL 8148
FEP替代品
介电常数低
高挤出速度和薄壁性能
耐化学性
耐低温
分类电缆
数据电缆系统的绝缘和交叉网
卤素到全空气性能 UL 444Maxxam™ FR 0587-21 R3
低烟无卤 UL 444Maxxam™ FR 0521-48 R1
可发泡 满足客户特定的阻燃要求Maxxam™ SY 89-22-7
耐恶劣环境、化学品和阳光照射
耐低温脆性(LTB)
低烟低毒
光纤电缆
低烟雾、无卤 满足客户特定的阻燃要求ECCOH™ 6649 UV Low DD
灵活性高
介电常数低
单元结构均匀
耐压耐热
同轴电缆
阻燃、柔性 建筑和工程、工业、核能FireCon™ CPE 37-36 RoHS 黑色
FireCon™ CPE 30-20 RoHS 自然色 阻燃、柔性
建筑和工程、工业、核能
光纤、管道
工业, Teck 90电线
特点 细分市场和用途
ECCOH™ 5549 UV
ECCOH™ 6649 UV Low DD
ECCOH™ 5981 UV
Synprene™ RT5180
Synprene™ RT5180UV
Synprene™ RT3870M
阻燃、柔性 建筑和工程、工业、核能FireCon™ CPE 30-33 RoHS 黑色
耐恶劣环境、化学品和紫外线降解
耐低温脆性(LTB)
低烟低毒
灵活性高
易着色
低压和中压护套
电力和数据电缆系统护套
+86 021 60284888
www.avient.com
版权所有©2023埃万特公司。
https://www.avient.com/sites/default/files/2022-07/MEVOPUR Chemical Foaming Agents Application Bulletin_CN.pdf
在不限制本声明的一般性的情况下,不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用:
(1) 接触人体组织或体液长达30天或更长时间;
(2)“整形”(整容或重建)手术;
(3) 生殖植入物或任何节育器械;或者
(4) 用于支持或维持人类生命的永久性(超过30天)植入式医疗器械中的任何关键组件。
https://www.avient.com/sites/default/files/2022-05/MEVOPUR LQ for Silicone Elastomers_CN.pdf
在不限制本声明的一般性的情况下,不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用:
(1) 接触人体组织或体液长达30天或更长时间;
(2)“整形”(整容或重建)手术;
(3) 生殖植入物或任何节育器械;或者
(4) 用于支持或维持人类生命的永久性(超过30天)植入式医疗器械中的任何关键组件。